


# TB/HIV

## A CLINICAL MANUAL

TB/HIV



second edition



WORLD HEALTH ORGANIZATION

# **TB/HIV**

## **A CLINICAL MANUAL**

**Second edition**

Stop TB Department  
Department of HIV/AIDS  
Department of Child and Adolescent Health and Development



World Health Organization  
Geneva

*Writing team:*

**Anthony Harries**

Adviser to National Tuberculosis Control Programme, Lilongwe, Malawi

**Dermot Maher**

Stop TB Department, World Health Organization, Geneva, Switzerland

**Stephen Graham**

Wellcome Trust Research Laboratories, Blantyre, Malawi and  
Liverpool School of Tropical Medicine, Liverpool, England

*With contributions from:*

**Mario Raviglione and Paul Nunn**

Stop TB Department

**Charles Gilks**

Department of HIV/AIDS

**Shamim Qazi and Martin Weber**

Department of Child and Adolescent Health and Development  
World Health Organization

**Eric van Praag**

Family Health International, Washington DC, USA

*And forewords by:*

**Dr JW Lee** (2<sup>nd</sup> edition)

**Sir John Crofton** (1<sup>st</sup> edition)

*Acknowledgments:*

We gratefully acknowledge the helpful comments and suggestions of  
Drs Kevin de Cock, Robert Colebunders, Peter Donald,  
Malgosia Grzemska, Fabio Scano, Robert Scherpbier, Jeffrey Starke and  
Mukund Uplekar who reviewed the manuscript.

## **WHO Library Cataloguing-in-Publication Data**

TB/HIV: a clinical manual / writing team:

Anthony Harries, Dermot Maher and Stephen Graham. - 2nd ed.

I. Tuberculosis, Pulmonary 2. Tuberculosis 3. HIV infections 4. AIDS-related opportunistic infections 5. Antitubercular agents 6. Anti-retroviral agents 7. Delivery of health care, Integrated 8. Manuals I. Harries, Anthony II. Maher, Dermot. III. Graham, Stephen.

ISBN 92 4 154634 4

(NLM classification: WF 200)

### **© World Health Organization 2004**

All rights reserved. Publications of the World Health Organization can be obtained from Marketing and Dissemination, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 2476; fax: +41 22 791 4857; email: [bookorders@who.int](mailto:bookorders@who.int)). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to Publications, at the above address (fax: +41 22 791 4806; email: [permissions@who.int](mailto:permissions@who.int)).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

The World Health Organization does not warrant that the information contained in this publication is complete and correct and shall not be liable for any damages incurred as a result of its use.

The named authors alone are responsible for the views expressed in this publication.

Printed in China

<b>Foreword to second edition</b> . . . . .	11
<b>Foreword to first edition</b> . . . . .	12
<b>Preface to second edition</b> . . . . .	13
<b>Glossary and abbreviations</b> . . . . .	15
<b>Introduction</b> . . . . .	21
<b>I Background information on tuberculosis and human immunodeficiency virus</b> . . . . .	23
1.1 Tuberculosis . . . . .	23
1.1.1 Basic facts about TB . . . . .	23
1.1.2 Pathogenesis of TB . . . . .	25
1.2 Human immunodeficiency virus . . . . .	27
1.2.1 Introduction: HIV and AIDS . . . . .	27
1.2.2 HIV/AIDS epidemiology . . . . .	28
1.2.3 HIV transmission . . . . .	28
1.2.4 Prevention of HIV transmission in health units . . . . .	29
1.2.5 Immunopathogenesis of HIV infection . . . . .	30
1.2.6 Natural history of HIV infection . . . . .	31
1.2.7 Clinical staging . . . . .	32
1.2.8 Epidemiological surveillance of AIDS . . . . .	35
1.3 HIV-related TB . . . . .	36
1.3.1 Epidemiology of coinfection of HIV and <i>M tuberculosis</i> . . . . .	36
1.3.2 HIV infection and risk of TB . . . . .	37
1.3.3 TB in the course of HIV progression . . . . .	37
1.3.4 Consequence of HIV/ <i>M tuberculosis</i> coinfection . . . . .	37
1.3.5 Impact of HIV on TB control . . . . .	37
1.3.6 Patterns of HIV-related TB . . . . .	38
1.3.7 Impact of TB on HIV . . . . .	39
<b>2 An expanded framework for effective tuberculosis control</b> . . . . .	41
2.1 Introduction . . . . .	41
2.2 Components of expanded TB control framework . . . . .	41
2.2.1 Goals of TB control . . . . .	42
2.2.2 Targets for TB control (cure and case detection) . . . . .	42
2.2.3 TB control policy package (the DOTS strategy) . . . . .	43

2.2.4	Key operations for DOTS implementation. . . . .	44
2.2.5	Indicators to measure NTP progress in TB control . . . . .	45
2.3	Directly observed treatment . . . . .	45
2.4	TB/HIV . . . . .	46
2.5	DOTS-Plus. . . . .	47
<b>3</b>	<b>Diagnosis of pulmonary tuberculosis in adults. . . . .</b>	<b>49</b>
3.1	Diagnostic approach . . . . .	49
3.2	Clinical features . . . . .	50
3.3	Diagnostic sputum smear microscopy . . . . .	51
3.4	Differential diagnosis of pulmonary TB. . . . .	54
3.5	Chest X-ray in diagnosis . . . . .	55
3.6	Radiographic abnormalities seen in pulmonary TB . . . . .	55
3.7	Differential diagnosis of chest X-ray findings . . . . .	56
3.8	The place of mycobacterial culture in the diagnosis of TB . . . . .	57
3.9	Sepsis and concomitant TB . . . . .	57
3.10	Distinguishing other HIV-related pulmonary diseases from pulmonary TB . . . . .	58
<b>4</b>	<b>Diagnosis of pulmonary tuberculosis in children . . . . .</b>	<b>61</b>
4.1	Epidemiology of childhood TB . . . . .	61
4.2	How does TB in children differ from TB in adults? . . . . .	62
4.3	Approach to diagnosis of TB . . . . .	63
4.4	Score system for diagnosis of TB in children . . . . .	66
4.5	Tuberculin skin test . . . . .	67
4.6	The decision to start TB treatment in children . . . . .	68
4.7	Impact of HIV on the diagnosis of TB in children. . . . .	69
4.8	Differential diagnosis of pulmonary TB in HIV-infected children . . . . .	70
4.9	Management of child contacts of infectious adults . . . . .	71
<b>5</b>	<b>Diagnosis of extrapulmonary tuberculosis in adults and children . . . . .</b>	<b>75</b>
5.1	Diagnostic approach . . . . .	75
5.2	Tuberculous lymphadenopathy . . . . .	75
5.3	Miliary (disseminated) TB. . . . .	78
5.4	Tuberculous serous effusions (pleural, pericardial, ascites) . . . . .	79
5.5	Tuberculous meningitis. . . . .	84
5.6	Other forms of extrapulmonary TB. . . . .	87
5.7	Further information on spinal, gastrointestinal and hepatic TB. . . . .	88

<b>6</b>	<b>Diagnosis of HIV infection in adults with tuberculosis</b>	<b>91</b>
6.1	Clinical recognition of HIV infection in TB patients	91
6.2	HIV testing	92
6.2.1	HIV antibody tests	92
6.2.2	Tests to detect the virus itself	93
6.2.3	Objectives of HIV antibody testing in TB patients	94
6.2.4	Strategy for HIV antibody testing in TB patients	94
6.2.5	Diagnosis of HIV infection in individual TB patients	95
6.3	HIV counselling	95
<b>7</b>	<b>Diagnosis of HIV infection in children with tuberculosis</b>	<b>99</b>
7.1	Clinical recognition of HIV infection in children with TB	99
7.2	HIV testing	100
7.3	Counselling	101
<b>8</b>	<b>Standardized tuberculosis case definitions and treatment categories</b>	<b>105</b>
8.1	Standardized case definitions	105
8.1.1	Introduction	105
8.1.2	Questions and answers about case definitions	105
8.1.3	Case definitions by site and result of sputum smear	106
8.1.4	Category of TB patient for registration on diagnosis	107
8.2	Standardized diagnostic categories	108
<b>9</b>	<b>Management of patients with tuberculosis</b>	<b>111</b>
9.1	Introduction	111
9.2	Modes of action of anti-TB drugs	112
9.3	TB treatment regimens	113
9.3.1	New cases	114
9.3.2	Re-treatment cases	114
9.3.3	Standard code for TB treatment regimens	114
9.3.4	Recommended treatment regimens	115
9.3.5	Use of streptomycin in areas of high HIV prevalence	117
9.3.6	Use of TB drugs in children	117

9.4	TB treatment regimens: questions and answers . . . . .	118
9.5	Use of anti-TB drugs in special situations . . . . .	120
9.6	The role of adjuvant steroid treatment: questions and answers . . . . .	121
9.7	Monitoring of TB patients during treatment. . . . .	122
9.7.1	Monitoring of patients with sputum smear-positive PTB . . . . .	122
9.7.2	Recording treatment outcome . . . . .	123
9.7.3	Cohort analysis: questions and answers . . . . .	124
9.8	Response of HIV-positive TB patients to anti-TB treatment . . . . .	124
<b>10</b>	<b>Side-effects of anti-tuberculosis drugs . . . . .</b>	<b>129</b>
10.1	Introduction. . . . .	129
10.2	Prevention of side-effects . . . . .	129
10.3	Where to manage drug reactions . . . . .	129
10.4	When to stop anti-TB drugs . . . . .	129
10.5	Side-effects of anti-TB drugs . . . . .	130
10.5.1	Side-effects of anti-TB drugs in HIV-positive TB patients . . . . .	131
10.6	Symptom-based approach to management of drug side-effects. . . . .	132
10.7	Management of skin itching and rash . . . . .	132
10.7.1	Treatment regimen includes thioacetazone . . . . .	133
10.7.2	Treatment regimen does not include thioacetazone. . . . .	133
10.8	Desensitization . . . . .	134
10.9	Management of hepatitis . . . . .	135
<b>11</b>	<b>Antiretroviral therapy for the treatment of HIV infection . . . . .</b>	<b>137</b>
11.1	Introduction. . . . .	137
11.2	Antiretroviral drugs . . . . .	138
11.3	Principles of ART . . . . .	138

11.4	Principles of a public health approach to ART . . . . .	139
11.5	Initiation of ART . . . . .	139
11.5.1	Adults and adolescents with documented HIV infection	140
11.5.2	Infants and children . . . . .	140
11.6	Recommended doses of ARV drugs . . . . .	141
11.6.1	Adults and adolescents . . . . .	141
11.6.2	Children. . . . .	142
11.7	Choice of ART regimen . . . . .	149
11.7.1	Adults . . . . .	149
11.7.2	Children. . . . .	150
11.8	Monitoring the efficacy of ART. . . . .	151
11.9	Adverse effects . . . . .	151
11.10	Interactions between ARV drugs and drugs used to prevent or treat opportunistic infections. . . . .	153
11.11	Antiretroviral drugs and TB treatment . . . . .	153
11.11.1	Drug interactions. . . . .	153
11.11.2	Treating TB and HIV together . . . . .	153
11.11.3	Immune reconstitution syndrome . . . . .	154
11.11.4	Options for ART in patients with TB . . . . .	154
<b>12</b>	<b>Treatment and prevention of other HIV-related diseases in TB/HIV patients . . . . .</b>	<b>157</b>
12.1	Introduction. . . . .	157
12.2	Clinical spectrum of HIV-related disease . . . . .	157
12.3	Sexually transmitted infections. . . . .	158
12.3.1	Syndromic management. . . . .	158

预览已结束，完整报告链接和二维码如下：

[https://www.yunbaogao.cn/report/index/report?reportId=5\\_29996](https://www.yunbaogao.cn/report/index/report?reportId=5_29996)

